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Abstract 
Pulmonary ventilation (V� I) in awake and sleeping goats does not change when antagonists to several excitatory 
G protein-coupled receptors are dialyzed unilaterally into the ventral respiratory column (VRC). Concomitant 
changes in excitatory neuromodulators in the effluent mock cerebral spinal fluid (mCSF) suggest 
neuromodulatory compensation. Herein, we studied neuromodulatory compensation during dialysis of agonists 
to inhibitory G protein-coupled or ionotropic receptors into the VRC. Microtubules were implanted into the VRC 
of goats for dialysis of mCSF mixed with agonists to either μ-opioid (DAMGO) or GABAA (muscimol) receptors. 
We found: (1) V�I decreased during unilateral but increased during bilateral dialysis of DAMGO, (2) dialyses of 
DAMGO destabilized breathing, (3) unilateral dialysis of muscimol increased V� I, and (4) dialysis of DAMGO 
decreased GABA in the effluent mCSF. We conclude: (1) neuromodulatory compensation can occur during 
altered inhibitory neuromodulator receptor activity, and (2) the mechanism of compensation differs between G 
protein-coupled excitatory and inhibitory receptors and between G protein-coupled and inotropic inhibitory 
receptors. 
1. Introduction 
From invertebrates to mammals, the excitability of neural circuits that govern motor outputs depends largely 
upon the local levels of excitatory and inhibitory neuromodulators. However, the mechanisms that regulate the 
local release of neuromodulators, or compensatory shifts in second messengers downstream of 
neuromodulatory receptors remain unclear. Gaining insight into regulation of neuromodulation is important to 
improve treatment of disorders such as epilepsy, depression, and Parkinson’s disease, as well as opioid induced 
respiratory depression; thus, there is a need for studies on control of neuromodulators. 
Data from rodent models suggests there is “neuromodulator interdependence”, whereby changes in the activity 
of one or more neuromodulatory receptors are compensated by changes in the release of other 
neuromodulators to maintain stable ventilation (Doi and Ramirez, 2008, Doi and Ramirez, 2010). This concept 
has also been studied in awake and sleeping goats by dialyzing atropine (50 mM) unilaterally into the ventral 
respiratory column (VRC) to reduce or block excitatory muscarinic receptor activity (Muere et al., 2013). Rather 
than a hypothesized decrease in pulmonary ventilation (V� I) and breathing frequency (f), atropine dialysis 
increased f and V� I (Muere et al., 2013) which could have been due to increases in the excitatory 
neuromodulators substance P (SP) and serotonin (5-HT) as measured in the effluent dialysate. Subsequent 
studies in this goat model found that a lower dose of atropine (5 mM), or selective M2 (methoctramine) or M3 
(4-DAMP) receptor antagonists had no effect on f and V� I, but increased SP in the effluent dialysate to a lesser 
extent than 50 mM atropine (Muere et al., 2015a). Moreover, dialysis into the VRC of antagonists to excitatory 
SP receptors (neurokinin-1; NK-1) or 5-HT receptors (5-HT2A) alone or in combination with 5 mM atropine did not 
affect f and V� I, but increased SP and decreased GABA in effluent dialysate (Muere et al., 2015b). These findings 
suggest that presumptive decreases in activity of one or more excitatory receptors are accompanied by changes 
in other neuromodulators to maintain f and V�I in awake and NREM sleep states which supports the concept of 
neuromodulator interdependence (Doi and Ramirez, 2008). In other words, there is “compensation” defined as 
no change in ventilation with dialysis of excitatory antagonists and that this may be due to the observed 
concomitant increase in excitatory (SP) and decrease in inhibitory neurotransmitters (GABA). 
The studies above examined the effects of blocking excitatory, G protein-coupled neuromodulatory receptors. It 
is unknown whether increased activation of inhibitory receptors in the VRC will also elicit compensatory changes 
in neuromodulators and/or affect f and V� I. Widely expressed in the VRC are μ-opioid inhibitory receptors (Krause 
et al., 2009a, Pattinson, 2008), which are also G protein-coupled receptors (GPCRs). When activated, μ-opioid 
receptors act through second messenger cascades to reduce intracellular calcium and increase potassium efflux 
to decrease cellular activity (Pattinson, 2008). Administration of μ-opioid receptor agonists to the preBӧtzinger 
Complex (preBӧtC) region of the VRC has, in some studies, caused respiratory depression (Montandon and 
Horner, 2014, Montandon et al., 2011, Pattinson, 2008). However, other studies found that eupneic breathing is 
unchanged (Krause et al., 2009a) or increased with μ-opioid receptor agonists administration to the 
preBӧtC/VRC (Mustapic et al., 2010). The absence of a depression of breathing with increased μ-opioid receptor-
mediated inhibition could be due to neuromodulatory compensation. 
Another endogenous inhibitory neuromodulator controlling breathing is ϒ-aminobutyric acid (GABA) acting at 
GABAB metabotropic receptors to regulate neuronal membrane potential. However, acting through GABAA 
ionotropic receptors, GABA also directly affects neuronal activity by altering intracellular chloride (Tillakaratne et 
al., 1995). It is unknown whether neuromodulator interdependence occurs when the activity of ionotropic 
receptors is altered, and whether compensation occurs by similar or different mechanisms to increases in 
inhibitory signaling through GPCRs. 
Herein we studied whether neuromodulatory compensation occurs in response to increased inhibitory receptor 
activity by unilaterally dialyzing the μ-opioid receptor agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) 
or the GABAA receptor agonist muscimol into the VRC while measuring breathing and neurochemicals in the 
effluent dialysate of awake and sleeping goats. We chose these inhibitory agonists due to lack of agreement 
among several previous studies on effects on respiratory control of these agonists (Curran et al., 2000, Gatti et 
al., 1987, Krause et al., 2009a, Lalley, 2003, Lalley, 2008, Montandon et al., 2011, Mustapic et al., 2010, Nattie 
and Li, 2000, Taylor et al., 2006, Yamada et al., 1981, Yamada et al., 1982). We hypothesized that f and V� I would 
not change during DAMGO or muscimol dialysis, but that there would be changes in neurochemicals in the 
effluent dialysate. We also hypothesized that the mechanism of compensation would differ between 
antagonism of GPCR and ionotropic receptors. 
Through bilateral dialysis of DAMGO, we also tested the hypothesis that increased activity of the contralateral 
VRC may contribute to the stable f and V�I during unilateral DAMGO dialysis. We did not test this same 
hypothesis for muscimol because of the large ventilatory and behavioral responses observed in some goats with 
unilateral muscimol dialysis (see Results). 
2. Methods 
2.1. Goats 
Fifteen adult female, non-pregnant goats with an average body weight of 51.0 +/− 8.5 kg were housed and 
studied in an environmental chamber with a fixed ambient temperature and alternating 12-h light-dark cycles 
set between 7am and 7pm. There was free access to food and water except for study periods and the 24 h 
preceding surgeries. All protocols and procedures utilized in this study were approved by the Medical College of 
Wisconsin Institutional Animal Care and Use Committee. 
2.2. Surgical procedures 
The goats were anesthetized with ketamine (IV), intubated, and mechanically ventilated with isoflurane in 100% 
oxygen for the duration of the surgery. Flunixin meglumine (2 mg/kg, IM) was administered once pre-operatively 
and for two days post-operatively for pain. To minimize infection, ceftriaxone (25 mg/kg, IV) in 100 mL saline 
was administered over 30 min twice daily at 8–12 h intervals for three days starting the morning of a craniotomy 
surgery. Subsequently, ceftiofur sodium (4 mg/kg, IM) and gentamycin (6 mg/kg, IM) were administered once 
daily for the remainder of the study period. To minimize intracranial edema following the craniotomy, 
dexamethasone (4 mg/mL, IV) was administered three times daily and tapered for a week following surgery. 
Surgical sites were treated daily for 7 days with triple antibiotic ointment. Rectal temperature (TR), heart rate 
(HR), and oxygen saturation were continuously monitored during surgery. Over the following 24 post-operative 
hours these variables were monitored at predetermined intervals. 
Under sterile conditions, two surgeries were performed separated by two weeks. During one surgery, an incision 
was made in the goat’s neck to locate the carotid artery which was subsequently dissected out, elevated to 
beneath the skin, and sutured to the overlaying skin before closing the incision. Also, electroencephalographic 
(EEG) and electrooculographic (EOG) electrodes were inserted into the midline cranium and the superior orbital 
ridge for recordings to score wakefulness/sleep during night studies. The electrodes were attached to screws, 
secured with dental acrylic, and the wires were pulled through the skin prior to closure of the incision. 
In a second surgery two weeks later, stainless steel microtubules (70.0 mm length, 1.27 mm outer diameter, 
0.84 mm inner diameter) were chronically implanted unilaterally (n = 3) or bilaterally (n = 12) into or near the 
preBӧtC of the VRC (Fig. 1A & B). An incision was made that bisected the nuchal ligament along the dorsal 
midline of the skull and neck. A rotary drill was used to create an occipital craniotomy for visualization of the 
dura which, when opened, exposed the dorsal medulla. Obex served as an anatomical reference for 
micromanipulator controlled microtubule placement into the VRC. The target for placement was the preBӧtC 
which in goats is approximately 2.5–3.5 mm rostral from obex, 4.0–5.0 mm lateral from the midline and 4.0–
6.0 mm from the dorsal surface of the medulla (Krause et al., 2009a, Wenninger et al., 2004). However, in some 
cases adjustments in microtubule placement had to be made to avoid blood vessels. Following microtubule 
placement, screws were inserted into the skull to which the microtubules were chronically secured using dental 
acrylic. Stainless steel stylets, slightly shorter than the microtubules, were inserted into the microtubules and 
the incisions sutured closed. Following the procedure, post-operative monitoring and medications were 
administered as described above. 
 
Fig 1. A and B show sections of the goat medulla at two rostral to caudal distances from obex depicting the microtubule 
location in which DAMGO or muscimol were dialyzed unilaterally (1A) and bilaterally (1B). Each goat was numbered for 
unilateral and bilateral studies, and the numbers for the left and right microtubule are located in the images where the 
distal end of the microtubule was identified by post mortem histological analysis. The 0.5 mm wide porous membrane of 
the dialysis probe extended 2 mm beyond the distal end of the microtubule; thus, we inserted a 2 mm long, 1 mm wide 
gray filled rectangle for each number to represent a conservative estimate of the region of diffusion of the dialyzed 
substances (see text for basis of minimal diffusion). The circle in each image is the approximate location of the VRC in goats. 
The inset in 1A and 1B is the quantitation of the breathing frequency responses to mCSF and NMDA (mCSF/NMDA) 
injections displayed as percent of control. Goats number 7 and 10 were included in both groups of studies. 
 
2.3. Physiological studies 
The goats were acclimated to study protocols and equipment during the weeks of recovery from surgery. To 
obtain ventilatory data, a custom fitted mask was secured to the goat’s muzzle. A two-way breathing valve was 
inserted into the front of the mask with hoses attached to the inlet and outlet of the valve. For all studies, 
normal room air was inhaled though the inlet hose which was attached to a pneumotachograph connected to a 
computer. Windaq data acquisition software was utilized for breath-by-breath recording of inspiratory flow for 
computation of inspiratory (TI) and expiratory (TE) time, breathing frequency (f), tidal volume (VT), mean 
inspiratory flow rate (VT/TI) and inspiratory minute ventilation (V�I). The outlet hose was attached to a Tissot 
spirometer for collection of expired air (the volume of which was measured at 5 min intervals). Expired air was 
analyzed for O2 and CO2 concentration and those values were used to calculate O2 consumption and CO2 
excretion. In several goats, heart rate (HR) and blood pressure (BP) were recorded via an indwelling catheter 
secured in the elevated carotid artery (which also facilitated blood sampling). Arterial blood samples were 
analyzed for pH, paCO2, paO2, and O2 saturation using a Siemens RapidLab248 blood gas analyzer. For 
night/sleep studies, the only change was the addition of EEG and EOG wires attached to the implanted 
electrodes. Rectal temperature was routinely recorded. 
Dialysis probes (Harvard Apparatus, formerly CMA microdialysis, Holliston MA) inserted into the microtubules 
were 72 mm in length, 70 mm of which is a stainless-steel tube and the final 2 mm is a semi-permeable 
membrane (membrane diameter 0.5 mm, 20kda cut-off, 3 μL internal volume). Only the 2 mm membrane 
penetrated the brain tissue. During studies, the perfusate was either mock cerebral spinal fluid (mCSF: 124 mM 
NaCl, 2.0 mM KCL, 2.0 mM MgCl2, 1.3 mM K2PO4, 2.0 mM CaCl2, 11 mM glucose, 26 mM NaHCO3− and pH 7.32 in 
sterile distilled H2O) alone or with the μ-opioid agonist DAMGO (10, 50 or 100 μM, Sigma-Aldrich: E7384) or the 
GABAA agonist muscimol (0.5, 1.0, or 10.0 mM, Abcam: ab120094). The solutions were prepared in a tonometer 
flask, warmed to 39 °C, and equilibrated with 6.4% CO2 and 12% O2 balance N2. A syringe pump (Harvard 
Apparatus) delivered the dialysate to the dialysis probe at a flow rate of 25 μL/min. To minimize distraction of 
the goat, the pump was outside of the chamber; thus, a 150 cm length of polypropylene tubing (PE50) was 
needed to connect the syringe to the probe. The length of the tubing caused a delay of about 20 min between 
the start of dialysis and the arrival of perfusate at the probe tip. Moreover, during the initial 15–20 min of hour 
three, drug delivery to the tissue would continue as in hour 2. In addition, thereafter washout of the drug from 
the tissue would be time-dependent. As a result, the temporal pattern of ventilatory responses (shown in 
Figures and Tables) likely reflect these drug delivery and washout characteristic. To collect effluent dialysate, a 
short length of tubing was attached to the outlet end of the probe which was then attached to a modified 
cryotube. Separate tubes were used for effluent collection during each hour of dialysis. The effluent was then 
aliquoted and frozen at −80 °C for subsequent analysis by department biochemical core lab facilities. 
We performed uni- and bilateral dialysis of DAMGO, but dialysis of muscimol was only unilateral for reasons 
stated in the introduction. Provided in Table 1 is a list of studies which were completed on each of the 15 goats. 
Thirty minutes after probe insertion, we collected data over a fifteen-minute pre-dialysis control period which 
was followed by three continuous hours of dialysis. Hour 1 was mCSF alone, hour 2 was mCSF alone or mCSF 
mixed with a drug, and hour 3 was again mCSF alone. DAMGO dialysis was at concentrations of 10, 50, or 
100 μM which is over the range and duration others used in dialyses studies on rats or dogs (Montandon et al., 
2011, Mustapic et al., 2010). Muscimol dialysis was at concentrations of 0.5, 1.0, or 10.0 mM which is over the 
range and duration others used in studies on awake and sleeping rats and piglets (Curran et al., 2001, Nattie and 
Li, 2008, Taylor et al., 2006). Day studies were completed between 9 AM and 2 PM. Night studies were 
completed between 7 P.M. and 2 A.M. A minimum of 36 h was allowed between consecutive studies on 
individual goats. 
Table 1. This table summarizes which studies each of the fifteen goats completed. Abbreviations are as follow: u 
denotes unilateral dialysis, b denotes bilateral dialysis, L and R denote dialysis on the left and right side 
respectively, and mCSF denotes mock cerebral spinal fluid.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4. Neurochemical analyses 
To measure the amino acids glutamine (GLN), glycine (GLY) and GABA present in effluent dialysate reverse phase 
high performance liquid chromatography was used as published by Muere et al. with fluorescent detection 
using: Waters Resolve C18 column (150 × 3.9) and a fluorescent detector with excitation at 229 nm and emission 
at 470 nm, β-alanine internal standard was used with O-phthaldialdehyde derivatization (Muere et al., 2013). To 
measure 5-HT and its metabolite HIAA, an identical column was used but the potential was set at 0.6 V vs. an 
Ag/AgCl reference electrode and a N-methylserotonin internal standard was used. A commercially available 
assay (Enzo Life Sciences, Assay Designs 900-018, range 9.76–10,000 pg/mL) and a microplate reader at 405 nm 
were used to determine SP levels. Measurement of norepinephrine, dopamine and their metabolites (DOPAC 
and HVA) was accomplished by using a Waters μBondapak C18 column (300 × 3.9), potential setting of 0.65 V vs 
Ag/AgCL reference electrode, and a 2, 5-dihydroxybenzylamine hydrobromide internal standard. 
Microtubule location was determined both functionally and histologically. Functional determination was 
accomplished via injections of N-methyl-d-aspartic acid (NMDA). The rationale for NMDA injections was based 
on previous findings that glutamate receptor agonist injections into the preBötC elicits a tachypneic ventilatory 
response (Krause et al., 2009b, McCrimmon et al., 2000, Solomon et al., 1999, Wenninger et al., 2004) thus, to 
approximate microtubule placement relative to the preBötC, 500 nL injections were made of mCSF alone or 
mixed with NMDA (100 mM). These injections were made in the awake state at least two weeks after 
microtubule implantation when the goat had recovered from the surgery. Injection tubes were inserted only to 
the distal end of the microtubule to avoid tissue damage. Breathing was monitored continuously during a 30-
min control period and over two hours during which, at 30 min intervals, either mCSF or NMDA was injected 
unilaterally. 
A post-mortem histological determination of microtubule location was also performed in each animal. The 
cerebral circulation was isolated under deep anesthesia before flushing the brainstem with phosphate buffered 
saline, followed by 4% paraformaldehyde in PBS following euthanasia. The brainstems were then extracted, 
dehydrated in successive 20 and 30% sucrose solutions at 4 °C and then frozen (−80 °C). The brainstems were 
serially sectioned at 25 μM in the transverse plane. One series was used for Nissl (cresyl violet) staining to 
determine microtubule (MT) placement. Nissl-stained images (scanned resolution of 4000 dots/inch) of the 
entire microtubule tract were captured (Nikon Super Coolscan 9000). Image software (Metamorph) was used to 
calibrate and measure microtubule placement in millimeters (relative to the midline and the ventral medullary 
surface) near the middle of the rostral-caudal MT damage range. 
2.5. Data and statistical analyses 
A pump with a known airflow rate was used to calibrate the inspiratory flow signal for breath by breath 
calculation of V�I, f, VT, TI, TE and VT/TI, using custom designed software programs. The EEG and EOG signals were 
utilized by a single investigator to score sleep state for each breath for night studies. Individual breath 
ventilatory data were averaged into 5 and 15 min bins. For all ventilatory variables, metabolic rate (V�O2), arterial 
blood gases, arterial blood pressure (BP), heart rate (HR), and rectal temperature (TR), a two-way repeated (RM) 
measures ANOVA compared all drug (DAMGO or muscimol) doses to mCSF alone (one factor repetition with 
dose and time as factors). Statistical analyses were over different portions of the predialysis period and 3-h 
dialysis protocol. The interaction P values indicated whether there were statistically significant differences 
between mCSF alone and mCSF mixed with drugs. For night studies, interaction term P values from two-way RM 
ANOVAs (two factor repetition, state and time as factors) were performed to determine the effect of sleep state 
on ventilatory variables. Statistical analyses were on absolute values for each variable and again for each 
variable during hours 2 and 3 of the protocol expressed as a percent of the variable over the last 15 min of hour 
1. Variability in ventilatory parameters was quantified using the coefficient of variation (CV). The CV was 
determined for all breaths during 5 min intervals. A two-way RM ANOVA (with dose and time as factors) was 
used to determine if significant interactions occurred resulting from DAMGO or muscimol dialysis. Holm-Sidak 
post hoc tests were used where appropriate after each ANOVA. 
2.6. Neurochemical analysis 
For statistical analyses of neurochemical data, two-way RM ANOVAs (one factor repetition, dose and time as 
factors) were used. The P values of the interaction term of ANOVA indicated whether the effect on effluent 
neurochemical concentration over time of antagonist dialysis was significantly different from that of the time-
control studies. This analysis was performed for SP, 5-HT, GLY, GABA, and norepinephrine for both muscimol and 
DAMGO studies. Also, we computed the change in each neurochemical between pre and post dialysis of DAMGO 
and muscimol, and then used a one-way ANOVA (drug as factor) to determine whether the neurochemicals 
significantly changed. 
3. Results 
3.1. Placement of microtubules (MTs) 
Shown in Fig. 1A and B are representative transverse sections of the goat medulla in which the location of the 
distal end of the histologically identified microtubule tract is identified for each animal (represented by number). 
The dialysis membrane extended 2 mm beyond (ventral) the dorsal-most aspect of the microtubule implantation 
site. We did not measure drug diffusion in this study, but conservatively estimated an affected region (Fig. 1) 
based on our previous dialysis studies in which we measured brain pH changes at two distances that resulted 
from dialysis of CO2-enriched mCSF (Hodges et al., 2004). In that study, we measured a dose-dependent 
decrease in extracellular fluid pH ∼220 μm from the dialysis probe when 25% or 80% CO2 was dialyzed, but 
simultaneous measurements of pH at a distal brainstem site (∼1.4 mm) from the site of focal acidosis indicated 
no detectable change in pH. Accordingly, we conservatively estimate a minimal diffusion of DAMGO to be 
∼0.25 mm from the dialysis probe recognizing that others in rats have found greater DAMGO diffusion distance 
(1.5–2.0 mm) from the dialysis probe (Montandon et al., 2011). We included a 2 × 1 mm gray box which 
represents a minimal estimate of the affected brainstem region relative to the estimated location of the VRC 
(circle). However, our model of pH changes with dialysis of acidified mCSF may underestimate the diffusion area 
as the in vivo brainstem has great capacity to buffer protons but there is no comparable uptake of DAMGO. 
As indicated in Table 1, we unilaterally dialyzed on both sides of the VRC in six goats and in four other goats, 
unilateral dialysis was only on one side; thus, there were 16 sites of unilateral dialysis. Of these sixteen, eleven 
were in the estimated affected regions. (Fig. 1A). Bilateral dialysis was in seven goats. Thirteen of the fourteen 
estimated affected regions for the bilateral studies (Fig. 1B) reached the VRC. 
As in past studies, we used the breathing frequency response to the glutamate receptor agonist NMDA as a 
functional marker of proximity to the preBӧtC. We found breathing frequency increased at least 10% after 
twenty-two of thirty-one NMDA injections made in the fifteen goats (insets Fig. 1A and B). In contrast, when 
only mCSF was injected, breathing frequency increased more than 10% in only two of the thirty-one injections. 
The variation in the responses to NMDA and the variation in histologically identified MT placement suggests that 
the dialyzed receptor agonists likely were not restricted to the targeted preBötC or the VRC in all goats. This 
possibility is a limitation of our study and will subsequently be discussed. 
3.2. DAMGO microdialysis 
There were no effects of time or dose (no significant interaction term; P > 0.05) in the two-way repeated (RM) 
measures ANOVA comparing absolute values measured during unilateral dialyses of mCSF alone or three doses 
of DAMGO (Table 2). Moreover, when the physiologic responses during and after unilateral DAMGO dialysis 
were normalized to Hour 1 control values (immediately prior to DAMGO dialysis), there also was no significant 
effects of time and dose for V� I, f, VT, (Fig. 2) or any other measured physiologic parameter. However, we noted a 
consistent trend for a transient reduction in V� I during the final 30 min of 50 μM and 100 μM DAMGO dialyses. 
The individual goat data suggested there were differences between goats in the time within this period when V� I 
was reduced; thus, a moving time average was computed for 3 successive 5 min intervals, which is shown in Fig. 
3. Using this approach, there was a significant difference in the V� I responses among mCSF dialysis and the 3 
doses of DAMGO (P = 0.042) (one-way ANOVA, dose as factor). The post hoc test indicated that the response to 
mCSF dialysis differed significantly from 50 μM DAMGO dialysis. Finally, dialysis of DAMGO destabilized 
breathing (Fig. 4), where the coefficient of variation in f during and after the last 30 min of DAMGO dialysis was 
significantly (P < 0.042) increased compared to mCSF dialysis. 
Table 2. Average of raw values for physiologic variables obtained during studies testing the effect of unilateral 
dialysis of DAMGO into the ventral respiratory column of awake goats. Presented are data for four, fifteen 
minute time periods for each of four studies (A–D). The first period of each study was predialysis control. During 
the subsequent periods of all studies, mock cerebral spinal fluid (mCSF) was dialyzed. During period 3 of studies 
B-D, DAMGO was added to the mCSF to provide concentration of 10 μM, 50 μM or 100 μM. Abbreviation of 
physiologic variables are defined in the text. For all variables, there was no statistically significant (P > 0.05) 
interaction value from the two-way repeated measures ANOVA (time and study as factors) comparisons of all 4 
studies. For Study A n = 7, Study B & C n = 8, and Study D n = 9. 
 
 
 
 
  
 
 
 
 
 
Fig. 2. Unilateral dialysis during the day of 100 μM DAMGO (n = 9, filled circles) did not significantly (P ≥ 0.758) alter 
ventilation (V�I, panel A), breathing frequency (f, panel B) or tidal volume (VT, panel C) compared to dialysis of mCSF alone 
(n = 7, open circles). Data are means ± SE. The x Axis is time from start of 180 min of dialysis. As indicated by the black line, 
100 μM DAMGO was dialyzed between 60 and 120 min. The values shown during and after DAMGO dialyses are the 
percent of the last 15 min prior to DAMGO dialyses. F and P values are the interaction term obtained from two-way 
repeated measures ANOVA using time and dose as factors. Note the trend of a transient reduction in V�I and f over the last 
30 min of DAMGO dialysis. 
 
Fig. 3. Because of the trend of a transient reduction in V�I over the last 30 min of DAMGO dialysis (Fig. 2), a moving time 
average was computed using 3 successive 5 min intervals and the lowest value for each goat over the last 30 min of 
DAMGO dialysis and mCSF are plotted in this figure (filled circles). Average values for each dose of DAMGO are plotted 
using mean symbols, data are means ± SE. One-way ANOVA indicated V� I as a percent of control differed significantly 
(P < 0.042) over the 4 conditions shown. The post hoc test indicated the responses to 0 and 50 μM differed significantly 
(P < 0.05). 
 
Fig. 4. Visual inspection of ventilatory tracings indicates variability of breathing increased during and after unilateral dialysis 
of 100 μM DAMGO. The four tracings were from a single goat for a portion of the last 15 min of the predialysis control 
period (panel A) and the last 15 min of each of three hours of mCSF dialysis (panels B–D) with DAMGO increased during the 
second of the three hours (Panel C). 
There were significant (P < 0.05) effects of time and drug for V� I, f, TI TE, and VT/TI when comparing bilateral 
dialysis of mCSF with bilateral dialysis of 100 μM DAMGO during the day. Expressing the data as absolute values 
over the entire study protocol (Table 3), or when expressed as percent of control values immediately prior to 
DAMGO dialysis (Fig. 5, Fig. 6), we found that bilateral dialysis of 100 μM DAMGO during the day significantly 
(P < 0.05) increased V� I, f, TE, and VT/TI and decreased TI. Bilateral dialysis of DAMGO also destabilized breathing 
(Fig. 7), where the coefficient of variation of V� I and f (Fig. 8) were significantly (P < 0.001) greater during the hour 
after bilateral DAMGO dialysis compared to the hour after mCSF dialysis. There were no significant (P ≥ 0.516) 
changes in any other measured variable during bilateral dialysis of DAMGO during the day (Table 3). 
Table 3. Averages of raw values for physiologic variables obtained during studies testing the effect of bilateral 
dialysis of DAMGO into the ventral respiratory column of awake goats. Presented are data for four, fifteen 
minute time periods for each of two studies (A and B). The first period of each study was predialysis control. 
During the subsequent three periods of both A and B studies, mock cerebral spinal fluid (mCSF) was dialyzed. 
The only difference between A and B was in study B when DAMGO was added to the mCSF in period 3 to obtain 
a concentration of 100 μM. Abbreviation of physiologic variables are defined in the text. Results of statistical 
analyses using two-way repeated measures ANOVA (time and study as factors) indicated there was a significant 
interaction term for V� I, (P = 0.025), f (P = 0.019), and TI (P = 0.007). There were significant (P < 0.05) effects of 
time indicated as follows: * 4 differed from 1, ** 4 differed from 1 and 2, and ***1 differed from 2, 3, & 4. For 
Studies A & B n = 7. 
 
 
Fig. 5. Bilateral dialysis of 100 μM DAMGO during the day (filled circles, n = 7) significantly (P < 0.002) increased ventilation 
(V�I, panel A) and breathing frequency (f, panel B) but did not alter (P < 0.446) tidal volume (VT, panel C) compared to dialysis 
of mCSF alone (open circles, n = 7). Data are means ± SE. Dialysis of 100 μM DAMGO occurred between 60 and 120 min 
(indicated by solid line). The values shown during and after DAMGO dialyses are the percent of the last 15 min prior to 
DAMGO dialyses. The F and P values are interaction terms from two-way repeated measures ANOVA using dose and time as 
factors. Asterisks denote values different between open and closed symbols ((P < 0.05), post hoc test). 
 
Fig. 6. Inspiratory time (TI), expiratory time (TE) and tidal volume/inspiratory time changed differently between bilateral 
dialysis of DAMGO (left panels) and unilateral dialysis of muscimol (right panel). Data are means ± SE. Bilateral dialysis of 
100 μM DAMGO (n = 7) during the day significantly (P < 0.001) decreased TI, increased TE during the post DAMGO dialyses 
period, and increased VT/TI during and after DAMGO dialysis. TI and VT/TI increased after muscimol dialysis while TE was 
significantly (P < 0.001) decreased during and after muscimol dialysis. Filled circles indicate studies during which 100 μM 
DAMGO was dialyzed during 60–120 min (solid line indicates period of DAMGO dialysis). Two-way repeated measures 
ANOVA was used to obtain F and P values and values shown are the interaction term of the ANOVA. Asterisks denote values 
different between open and closed symbols (P < 0.05, post hoc test). 
 
Fig. 7. Visual inspection of ventilatory tracings indicates variability of breathing increased and inspiratory time decreased 
during and after bilateral dialysis of 100 μM DAMGO. The four tracings were from a single goat for a portion of the last 
15 min of the predialysis control period (panel A) and the last 15 min of each of three hours of mCSF dialysis (panels B–D) 
with DAMGO increased during the second of the three hours (Panel C). 
 
Fig. 8. The coefficient of variation of ventilation (V�I, panel A) and breathing frequency (f, panel B) within 5 min periods was 
significantly (P < 0.001) greater during the period after bilateral 100 μM DAMGO dialysis than after bilateral mCSF dialysis. 
Data are means ± SE. The x Axis is time from start of 180 min of dialysis. As indicated by the black line, DAMGO was dialyzed 
between 60 and 120 min. The F and P values are interaction terms from two-way repeated measures ANOVA using dose 
and time as factors. Asterisks denote values different between open and closed symbols (P < 0.05, post hoc test). 
At night, for unilateral and bilateral (Fig. 9) dialysis of 100 μM DAMGO, there were no significant interaction 
terms in two-way ANOVA analysis (time and state as factors) when comparing responses during awake and 
NREM sleep (Table 4, Table 5). 
 
Fig. 9. During bilateral dialysis of 100 μM DAMGO (n = 7) at night, there were no significant (P ≥ 0.348) interaction terms for 
any ventilatory variable of the two-way ANOVA comparing awake and NREM sleep (state and time). Data are means ± SE. 
Data from each state were averaged in 15 min bins, the filled circles indicate the awake state and open circles indicate the 
NREM sleep state. Dialysis of 100 μM DAMGO occurred during minutes 60–120 of the study and is indicated by the solid 
line. 
Table 4. Average of raw values for physiologic variables obtained during studies testing the effect of unilateral 
dialysis of DAMGO into the ventral respiratory column of goats during awake and NREM sleep states. Presented 
are data for the last fifteen minutes of three hours of mCSF dialysis. During the second hour, DAMGO was added 
to the mCSF to provide a concentration of 100 μM. Abbreviation of physiologic variables are defined in the text. 
Ventilatory data were obtained on seven goats, but HR, BP, blood gases, and pH were obtained on only four 
goats. For all variables, there was no statistically significant (P > 0.05) interaction value from the two-way 
repeated measures ANOVA (time and study as factors) comparing awake and NREM sleep. 
 
Table 5. Average of raw values for physiologic variables obtained during studies testing the effect of bilateral dialysis of 
DAMGO into the ventral respiratory column of goats during awake and NREM sleep states. Presented are data for the last 
fifteen minutes of three hours of mCSF dialysis. During the second hour, DAMGO was added to the mCSF to provide a 
concentration of 100 μM. Abbreviation of physiologic variables are defined in the text. For all variables, there was no 
statistically significant (P > 0.05) interaction value from the two-way repeated measures ANOVA (time and study as factors) 
comparisons of all 4 studies. Ventilatory data were obtained on seven goats, but HR, BP, blood gases, and pH were only 
obtained on four goats. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During daytime unilateral DAMGO dialysis, a one-way ANOVA analysis of the change in GABA between pre and 
post dialysis of DAMGO indicated there was a significant (P < 0.020) decrease in GABA during dialysis of 50 μM 
and 100 μM DAMGO (Fig. 10). In addition, during both unilateral and bilateral dialysis of 100 μM DAMGO at 
night, there were significant (P < 0.001) decreases in GABA in the effluent mCSF. However, bilateral dialysis of 
100 μM DAMGO during the day did not significantly (P > 0.05) alter GABA. Lastly, there were no significant 
changes (P > 0.05) in 5-HT, SP, glutamine, glycine, dopamine, norepinephrine and the metabolites DOPAC, HIAA, 
and HVA in the effluent dialysate during DAMGO dialyses studies (data not shown). 
 
Fig. 10. Unilateral dialysis of 50 μM and 100 μM DAMGO during the day significantly (P < 0.02) decreased GABA in the 
effluent dialyzed mCSF. Data are means ± SE. On the x-axis are the DAMGO doses and y axis indicates the change in GABA 
between hours 1 and 3 of dialysis. Statistical analysis was by one-way ANOVA (drug as factor). 
3.3. Muscimol microdialysis 
A two-way ANOVA (time and dose as factors) indicated there were no significant (P > 0.05) differences in 
absolute values of physiologic variables between mCSF dialysis and dialysis of three muscimol concentrations 
(0.5, 1.0, or 10 mM) (Table 6). However, when variables during and after muscimol dialysis were expressed as a 
percent of the periods just prior to muscimol dialysis, there were significant effects of time and dose for V� I 
(P < 0.025) and f (P < 0.044) when all muscimol doses were compared and when each elevated muscimol 
concentration was individually compared to the mCSF study (Fig. 11, 1.0 mM shown). Expressed as percent 
change, only 0.5 mM muscimol significantly (P < 0.005) altered VT. All doses of muscimol significantly (P < 0.023) 
decreased TE but did not significantly (P ≥ 0.577) alter TI or VT/TI (Fig. 6). 
Table 6. Average of raw values for physiologic variables obtained during studies testing the effect of unilateral 
dialysis of muscimol into the ventral respiratory column of awake goats. Presented are data for four, fifteen 
minute time periods for each of four studies (A–D). The first period of each study was predialysis control. During 
the subsequent periods of all studies, mock cerebral spinal fluid (mCSF) was dialyzed. During period 3 of studies 
B–D, muscimol was added to the mCSF to provide concentrations of 0.5 μM, 1.0 μM or 10 μM respectively. 
Abbreviation of physiologic variables are defined in the text. For all variables, there was no statistically 
significant (P > 0.05) interaction value from the two-way repeated measures ANOVA (time and study as factors) 
comparisons of all 4 studies. For studies A–C n = 7, study D n = 6. 
 
 
 
  
 
 
Fig. 11. Unilateral dialysis of 1.0 mM (n = 7) muscimol (filled circles) during the day significantly increased ventilation (V�I, 
panel A, P = 0.025) and breathing frequency (f, panel B, P = 0.044) but did not alter tidal volume (VT, panel C, P = 0.196) 
compared to dialysis of mCSF alone (open circles) (n = 7). Data are means ± SE. The solid lines indicate the period during 
which muscimol was dialyzed (60–120 min). Two-way repeated measures ANOVA was used (dose and time as factors) to 
obtain F and P values. Asterisks denote values significantly different between open and closed symbols (P < 0.05, post hoc 
test). 
The highest concentration of muscimol (10.0 mM) induced varied degrees of behavioral excitability, nystagmus, 
spastic limb movements, and postural instability lasting up to 4 h following the completion of studies. In 3 of 9 
studies, these behavioral effects were too severe to warrant continuation of the study beyond the second hour. 
Two of the three animals had a dramatic increase in f accompanied by severe behavioral effects, while the third 
animal’s breathing frequency decreased eventually leading to terminal apnea. Despite these major behavioral 
changes, there were no significant changes during or after muscimol dialysis in all neurochemicals analyzed in 
the effluent mCSF, although norepinephrine increased in 4 of 6 goats during dialysis of 10.0 mM muscimol (data 
not shown). For all doses of muscimol, there were no significant (P ≥ 0.094) changes in PaO2, PaCO2, BP, HR, TR, 
or V�O2 (Table 6). 
4. Discussion 
Microdialysis of antagonists to excitatory, neuromodulatory, G protein-coupled receptors into the VRC of awake 
and sleeping goats (Langer et al., 2016, Muere et al., 2013, Muere et al., 2015a, Muere et al., 2015b, Muere et 
al., 2015c) support the concept of neuromodulator compensation, whereby decreases in excitatory receptor 
activity are compensated by increases in other (predominantly excitatory) neuromodulators to prevent a 
decrease in ventilation and breathing frequency (Doi and Ramirez, 2008, Doi and Ramirez, 2010). In other words, 
there is “compensation” defined as no change in ventilation with dialysis of excitatory antagonists and that this 
may be due to the observed concomitant increase in excitatory (SP) and decrease in inhibitory 
neurotransmitters (GABA). 
The objective herein was to determine whether compensation would also occur during VRC dialyses of agonists 
to inhibitory, G protein-coupled (μ-opioid) or inhibitory, ionotropic (GABAA) receptors in awake and sleeping 
goats. Ventilatory data indicated that what appears to be compensation occurred during dialysis of both types of 
inhibitory receptor agonists. Furthermore, it appears the compensation in neuromodulators differed between 
agonists to inhibitory G protein-coupled (μ-opioid) receptors and agonists of inhibitory ionotropic (muscimol) 
receptors. 
4.1. Ventilatory and neurochemical effects of opioids dialyzed into the VRC 
μ-opioid receptors are widely and abundantly expressed throughout respiratory control regions in the 
brainstem, including the preBötC region of the VRC (Gray et al., 1999, Haji et al., 2003, Krause et al., 2009a, 
Pattinson, 2008, Stornetta et al., 2003). These inhibitory, neuromodulatory receptors may contribute to the 
regulation of normal eupneic ventilation through the activity of endogenous opioids. The activation of these 
receptors also contributes to unwanted depression of ventilation with opiate use clinically, or cardiorespiratory 
failure in cases of opiate abuse/overdose. Previous studies have addressed the effects of exogenously applied 
opioid receptor agonists within the neural networks that control breathing, but these studies show inconsistent 
effects on ventilatory variables (Krause et al., 2009a, Lalley, 2008, Montandon et al., 2011, Mustapic et al., 2010, 
Pattinson, 2008). Montandon et al. dialyzed DAMGO into the preBötC of awake and anesthetized rats and found 
that breathing frequency was depressed at low concentrations, and found complete apnea at higher 
concentrations (Montandon et al., 2011). In contrast, Mustapic et al. reported that the injection of DAMGO into 
the preBötC of decerebrate (unanesthetized) dogs increased breathing frequency and phrenic nerve output 
(Mustapic et al., 2010). Different still were studies by Krause et al., in which DAMGO bilaterally injected into the 
preBötC of awake goats did not affect respiratory rhythm or pattern while breathing room air (Krause et al., 
2009a). Our current results differ from each of the above as unilateral DAMGO dialysis decreased ventilation, 
but bilateral dialysis increased ventilation, breathing frequency and ventilatory drive while it decreased 
inspiratory time. In addition, both unilateral and bilateral dialysis of DAMGO destabilized breathing frequency, 
which is similar to previous reports that opioids can cause increased variability or destabilization of breathing 
(Mitsis et al., 2009, Pattinson, 2008, van den Aardweg, 2009, Walker et al., 2007). Collectively, these data 
suggest that the effect of opioids on ventilation might differ between species, state of wakefulness, and the 
nature of the experimental preparation. 
During unilateral DAMGO dialysis, a local decrease in GABA (as indicated in the collected effluent mCSF, Fig. 10) 
may have provided neuromodulatory compensation for a presumed DAMGO-induced depression of ventilation 
(Fig. 3). In other words, an initial direct depression of ventilation (Fig. 3) by DAMGO may have been offset within 
minutes by a secondary/compensatory decrease in GABA or by a change in another neurochemical to return 
ventilation to normal. This secondary/compensatory response may have been relatively greater with 100 μM 
compared to 50 μM which is why a significant depression in ventilation was found with 50 μM but not 100 μM 
DAMGO. A secondary/compensatory response is sufficiently rapid to prevent a detectable decrease in 
ventilation during dialysis of antagonists to excitatory neuromodulator receptors (Muere et al., 2013, Muere et 
al., 2015a, Muere et al., 2015b, Muere et al., 2015c). Compensation during DAMGO dialysis may also have been 
within the contralateral VRC. However, findings herein (Fig. 5) do not support this possibility as bilateral DAMGO 
dialysis increased ventilation. This finding is similar to bilateral dialysis of antagonists to excitatory receptors 
which also increased ventilation even though ventilation did not change during unilateral dialysis of these 
antagonists (Langer et al., 2016). Accordingly, during unilateral and bilateral dialysis, there likely are multiple 
factors affecting ventilation, which makes it difficult to measure a steady-state, maximal effect, or recovery 
effect. The cause of the increased ventilation with bilateral DAMGO was not associated with decreased GABA; 
thus, we speculate it is due to other mechanisms such as increases in excitatory neuromodulators not yet 
measured and/or changes in second messengers downstream of G protein-coupled neuromodulator receptors. 
We have no explanation for why the increased ventilation with bilateral DAMGO dialysis did not result in arterial 
hypocapnia even though metabolic rate did not change. Nevertheless, whatever the exact mechanism of the 
neurochemical response to perturbation of neuromodulator receptors, it does not appear unique to awake and 
NREM sleep states as Langer et al. found increases in 5-HT and SP equal in awake and anesthetized goats during 
dialysis of 50 mM atropine (Langer et al., 2016). 
Opioids administered clinically in humans for pain management clearly cause respiratory depression, and when 
given intravenously likely simultaneously depress multiple respiratory nuclei (Pattinson, 2008). Why does 
neuromodulator compensation not prevent this respiratory depression? It is not known whether 
neuromodulator compensation is widespread throughout the brain. Thus, the specific neural sites providing a 
tonic drive to breathe (chemoreceptors) and/or sites of respiratory-associated motor neurons (such as the 
hypoglossal nuclei) might not display neuromodulator compensation during opiate-induced depression, and 
thus could be the major substrate for respiratory depression during clinical intravenous opioid administration. 
Indeed opioid respiratory depression has been linked to increased incidence of obstructive sleep apnea and 
sleep disordered breathing (Randerath and George, 2012, Zutler and Holty, 2011), which as reported by Skulsky 
et al. (Skulsky et al., 2007) and Hajiha et al. (Hajiha et al., 2009) could be due to opioid depression of hypoglossal 
muscle activity. 
In reduced preparations opioids added to a perfusate of the medulla induced a quantal or step-wise, rather than 
progressive, slowing of respiratory frequency (Mellen et al., 2003). In awake goats quantal slowing does not 
occur during opioid administration to the VRC (which includes the preBötC). These findings suggest a 
fundamental difference in the effects of opioids between reduced and intact preparations. Indeed, an index of 
the drive to breathe (VT/TI) was increased during bilateral μ-opioid receptor stimulation, which likely represents 
the effects of compensation (or overcompensation) by neuromodulators. Moreover, the present findings 
demonstrate a fundamental difference between the effects of DAMGO and muscimol on respiratory drive and 
timing mechanisms. 
4.2. Ventilatory and neurochemical effects of unilateral muscimol dialysis in the VRC 
The current and past dialysis studies in unanesthetized goats found neuromodulator compensation during 
perturbation of G protein-coupled receptors (Muere et al., 2013, Muere et al., 2015a, Muere et al., 2015b, 
Muere et al., 2015c). Herein we found what could be interpreted as overcompensation for increases in 
inhibitory ionotropic GABA receptor activity during muscimol dialysis. Several previous studies (Akilesh et al., 
1997, Curran et al., 2000, Curran et al., 2001, Darnall et al., 2001, Gatti et al., 1987, Yamada et al., 1981, Yamada 
et al., 1982) found that administering muscimol to various brainstem regions depressed breathing and/or 
arousal from sleep. On the other hand, other studies (Nattie and Li, 2008, Taylor et al., 2006) found that 
administration of muscimol increased breathing and/or increased the ventilatory response to CO2 and hypoxia 
(Nattie and Li, 2000, Taylor et al., 2006). Our findings are similar to these latter studies as we found that 
muscimol dialysis increased ventilation and breathing frequency. 
We found no significant change in the levels of any measured neurochemicals in the effluent mCSF that could 
counter a depressant effect of muscimol on neuronal activity. However, 10.0 mM muscimol dialysis increased 
norepinephrine in effluent dialysate in 4 of 6 goats, which could have contributed to the increased V�I in these 
goats. A mechanism of GABA receptor-mediated increase in norepinephrine release has been proposed by 
Scatton and Bartholini, 1981 who found that administration of a GABA receptor agonist (Progabide) in the rat 
hypothalamus activated noradrenergic neurons and increased norepinephrine turnover (Scatton and Bartholini, 
1981). Another possible explanation is that muscimol acts on presynaptic GABA receptors to increase glutamate 
release and postsynaptic neuronal activity (Jang et al., 2006, Koga et al., 2005); thus, presynaptic, GABA-
mediated glutamate responses may contribute to the increased V� I and f for all doses of muscimol. The 
behavioral effects observed with muscimol dialysis could also be due to increased glutamate release, as these 
effects were similar to those observed by Wenninger et al. after injection of ibotenic acid (an excitatory 
neurotoxin which acts glutamate receptors) into the preBötC of goats (Wenninger et al., 2004). 
Irrespective of the mechanism and/or pathway, the ventilatory responses to muscimol indicate that some type 
of compensation and/or secondary effect exists to prevent respiratory depression during perturbations of 
inhibitory ionotropic receptors, which instead increased ventilation in the behaving goat. 
4.3. μ-Opioid and GABA receptor-mediated breathing instabilities 
There was significant ventilatory instability with dialyses of the μ-opioid receptor agonist (Figs. 4, 7, 8) and to 
some degree during muscimol dialysis. This instability contrasts to studies (Langer et al., 2016, Muere et al., 
2013, Muere et al., 2015a, Muere et al., 2015b, Muere et al., 2015c) in which dialyses of antagonists to multiple 
excitatory receptors in the VRC did not destabilize breathing. The destabilization with DAMGO could be due to 
time-dependent changes in the direct effect of opioid-induced depression and the indirect effect of potential 
compensatory mechanisms. Or a compensatory increase in an unknown excitatory neuromodulator may have 
created a “high-gain controller”, which destabilizes breathing (Asyali et al., 2002, Khoo, 2000). Finally, 
destabilization in the muscimol studies could be due to increased norepinephrine which during pathological 
states induced increased variability in breathing (Viemari et al., 2013, Zanella et al., 2014). 
5. Caveats and limitations 
We previously summarized (Muere et al., 2013, Muere et al., 2015a, Muere et al., 2015b, Muere et al., 2015c) 
the limitations and caveats of dialyses studies in the medulla of awake and sleeping goats. One limitation is that 
the microtubules were not all implanted at the same site (Fig. 1). The variation in placement was due primarily 
to the need for avoiding blood vessels on the dorsal surface during surgical implantation. A second limitation is 
the uncertainty of the exact boundaries of the targeted preBötC. To assess the proximity of the microtubule to 
the preBötC, we utilize the ventilatory response to the glutamate receptor agonist NMDA. Herein, there was a 
positive response to NMDA even in some goats (see # 11 and 15) whose post mortem histologic measurements 
indicated the microtubule was outside the estimated boundaries of the preBötC; thus, it is possible our 
anatomic estimate of the preBötC may be too restrictive. A third limitation is the study may have been under 
powered which could be why we did not detect a significant depression of ventilation with 100 μM unilateral 
dialysis of DAMGO even though there was a significant depression with 50 μM unilateral dialysis of DAMGO. A 
fourth limitation is uncertainty regarding the diffusion of the drugs dialyzed. A final limitation is that we 
currently only have the capability of measuring the selected neurochemicals in the effluent mCSF, and as a result 
we likely missed potential changes in other local neuromodulatory molecules. 
6. Summary and conclusions 
We found that: (1) V� I decreased during unilateral but increased during bilateral dialysis of DAMGO, (2) dialyses 
of DAMGO destabilized breathing, (3) unilateral dialysis of muscimol increased breathing and (4) dialysis of 
DAMGO decreased GABA in the effluent mCSF. We conclude: (1) neuromodulatory compensation can occur 
during altered inhibitory neuromodulator receptor activity, and (2) the mechanism of compensation differs 
between G protein-coupled excitatory and inhibitory receptors and between G protein-coupled and ionotropic 
inhibitory receptors, and (3) the effects of presumed perturbations of inhibitory receptor activity within the 
respiratory control network shown herein likely have general applicability to neuronal networks throughout the 
brain. 
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